GSK’s Witty has no interest in buying AstraZeneca

Thanks but no thanks. That was GlaxoSmithKline ($GSK) CEO Andrew Witty's comeback to the suggestion that maybe GSK should buy AstraZeneca ($AZN). They are both based in the U.K., and AstraZeneca is th…
Read the full story: News